Welcome to our dedicated page for Celldex Therapeutics news (Ticker: CLDX), a resource for investors and traders seeking the latest updates and insights on Celldex Therapeutics stock.
Celldex Therapeutics, Inc. reports developments as a clinical-stage biotechnology company focused on mast cell biology and antibody-based therapeutics for allergic, inflammatory, autoimmune and other mast cell-mediated diseases. Company updates center on barzolvolimab, a humanized monoclonal antibody being studied across chronic spontaneous urticaria, cold urticaria and symptomatic dermographism, as well as pipeline work that includes CDX-622 in asthma.
Recurring news themes include clinical data presentations at allergy and dermatology meetings, financial results, corporate updates and capital actions. Celldex also reports financing activity tied to its common stock and development priorities for its antibody-based immunology pipeline.
Celldex (NASDAQ:CLDX) reported long-term Phase 2 data for barzolvolimab in chronic spontaneous urticaria (CSU) with angioedema. Treatment produced rapid, significant and durable angioedema improvements that persisted seven months after final dosing.
Up to 64% of baseline angioedema patients were angioedema-free at Week 76. Two Phase 3 CSU trials (1,939 patients) are fully enrolled, with topline data expected in Q4 2026 and a planned BLA filing in 2027.
Celldex (NASDAQ:CLDX) reported first-in-human Phase 1 results for CDX-622, a bispecific antibody targeting soluble SCF and TSLP, at the EAACI 2026 meeting.
According to Celldex, CDX-622 produced rapid, profound, dose-dependent, durable serum tryptase reductions, showed monoclonal-like pharmacokinetics, and was well-tolerated without dose-limiting toxicities, serious related events, or immunogenicity. Non-human primate data supported selective mast cell depletion without measurable effects on spermatogenesis or melanogenesis.
Celldex (NASDAQ:CLDX) will present new data from its mast cell–targeting pipeline at the 2026 European Academy of Allergy and Clinical Immunology Congress in Istanbul, Türkiye, on June 12-15, 2026.
Three presentations cover barzolvolimab in chronic spontaneous and cold urticaria and first-in-human Phase 1 data for bispecific antibody CDX-622 in healthy volunteers.
Celldex (NASDAQ:CLDX) reported Q1 2026 results and an operational update on May 7, 2026. Key points: Phase 3 CSU enrollment finished six months early (1,939 patients), topline CSU data expected Q4 2026, BLA planned for 2027, multiple 2026 readouts expected, and a $345M follow-on financing closed in April 2026.
Cash as of March 31, 2026: $451.5M; net loss Q1 2026: $78.7M (−$1.18/share).
Celldex (NASDAQ:CLDX) management will appear in a fireside chat at H.C. Wainwright’s 4th Annual Inflammatory Skin Disease Virtual Conference on April 14, 2026 at 3:30 pm ET. The live webcast will be available in the Investors > Events & Presentations section and replays will remain for 90 days.
Celldex Therapeutics (Nasdaq: CLDX) closed an underwritten public offering of 11,896,750 common shares on April 6, 2026, including full exercise of the underwriters’ option for 1,551,750 additional shares.
The public offering price was $29.00 per share, and gross proceeds to Celldex were approximately $345 million, before underwriting discounts, commissions and offering expenses.
Celldex (Nasdaq: CLDX) priced an underwritten public offering of 10,345,000 shares at $29.00 per share, expected to raise approximately $300 million in gross proceeds before underwriting discounts. The underwriters have a 30-day option for an additional 1,551,750 shares. Closing is expected on or about April 6, 2026. Celldex said net proceeds will fund commercial readiness and a potential U.S. launch of barzolvolimab (if approved), ongoing clinical and preclinical development, expansion of its bispecific antibody platform, pipeline development, and general corporate purposes.
Celldex (Nasdaq: CLDX) on April 1, 2026 announced a proposed underwritten public offering of common stock, with underwriters granted a 30-day option to buy up to an additional 15% of offered shares.
All shares are being offered by the company; net proceeds are intended to fund commercial readiness and potential launch of barzolvolimab, ongoing clinical and preclinical development, bispecific platform growth, pipeline development, and general corporate purposes. Final terms depend on market conditions and will be disclosed in a prospectus supplement.
Celldex (NASDAQ:CLDX) presented Phase 2 data at AAD 2026 showing barzolvolimab produced rapid, profound and durable quality-of-life improvements in chronic spontaneous urticaria (CSU), cold urticaria (ColdU) and symptomatic dermographism (SD).
Key results: up to 51% complete response at Week 12 (CSU), 71% at Week 52, 41% maintained response seven months off therapy; ColdU/SD complete responses reached up to 66% and 49% at Week 20. DLQI domain scores improved across all six domains with many patients achieving DLQI 0/1.
Celldex (NASDAQ:CLDX) presented Phase 2 open‑label extension data at AAAAI 2026 showing that barzolvolimab retreatment produces rapid, profound efficacy similar to initial exposure in Cold urticaria (ColdU) and symptomatic dermographism (SD). In the OLE, complete response rates at Week 20 were 62% (ColdU) and 60% (SD), consistent with initial study results. Among prior complete responders, repeat complete response reached 82% (ColdU) and 86% (SD). Retreatment improved control (up to 68–69% well controlled) and was well tolerated. A global Phase 3 EMBARQ trial (NCT07266402) is enrolling.